CLINICAL TRIALS PROFILE FOR AURANOFIN
✉ Email this page to a colleague
All Clinical Trials for auranofin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00246064 ↗ | The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol | Completed | Centocor Ortho Biotech Services, L.L.C. | Phase 4 | 2001-12-01 | The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering. |
| NCT01419691 ↗ | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | Completed | Kansas Bioscience Authority | Phase 2 | 2011-09-01 | The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL). |
| NCT01419691 ↗ | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | Completed | The Leukemia and Lymphoma Society | Phase 2 | 2011-09-01 | The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL). |
| NCT01419691 ↗ | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | Completed | Therapeutics for Rare and Neglected Diseases (TRND) | Phase 2 | 2011-09-01 | The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL). |
| NCT01419691 ↗ | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | Completed | University of Kansas Medical Center | Phase 2 | 2011-09-01 | The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL). |
| NCT01737502 ↗ | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | Recruiting | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2012-11-29 | This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer. |
| NCT01737502 ↗ | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | Recruiting | Mayo Clinic | Phase 1/Phase 2 | 2012-11-29 | This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for auranofin
Condition Name
Clinical Trial Locations for auranofin
Trials by Country
Clinical Trial Progress for auranofin
Clinical Trial Phase
Clinical Trial Sponsors for auranofin
Sponsor Name
